Market Challenges And Opportunities

Intraocular Melanoma Treatment Market Drivers

Advancements in developing innovative treatment options in intraocular melanoma treatments such as understanding the molecular characteristics of intraocular tumor through genetic alternations and mutations studies in patients and novel therapies based on inhibition mechanism of expression of growth factor receptors such as c-Met and c-Kit, are being investigated to bring better treatment options for patients.

Moreover, rampant research pertaining to melanoma, increasing incidence burden of intraocular melanoma, and increasing number of clinical trials for new treatments, in turn, are expected to boost growth of the intraocular melanoma treatment market size over the forecasted period. For instance, according to the American Society of Clinical Oncology (ASCO), in 2015, around 3,540 adults (2,130 men and 1,410 women) in the U.S. were diagnosed with primary intraocular cancer. According to the American Academy of Ophthalmology (AAO), 2014 data findings, uveal melanoma is the most commonly diagnosed primary intraocular malignancy in adults, with 90% of uveal melanoma involving the choroid, 5% affecting the ciliary body, and 5% developing in the iris. Additionally, uveal melanoma accounts for 5%-10% of all melanomas. Additionally, according to the American Academy of Ophthalmology (AAO), 2014 data findings, incidence of intraocular melanoma is higher among the fairly pigmented groups while exceedingly lower among Asian and African population.

Intraocular Melanoma Treatment Market Restraints

High cost and negative side effects associated with treatment of intraocular melanoma coupled with poor reimbursement infrastructure are expected to limit growth of the intraocular melanoma treatment market in the near future.